Gülşen Akman‐Demir

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

Elaine F. Remmers, Fulya Coşan, Yohei Kirino et al. · Nature Genetics · 2010 · 645 citations · Full text

Inflammation, Immunogenetics, Mhc Class +12

Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis

Sven Jarius, Jette Frederikson, Patrick Waters et al. · Journal of the Neurological Sciences · 2010 · 168 citations

Ocular Disease, Prognostic Impact, Autoimmune Disease +10

Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders

Sven Jarius, Christian Jacobi, J. de Sèze et al. · Multiple Sclerosis Journal · 2011 · 166 citations

Interleukin-6 in neuro-Behçet’s disease: Association with disease subsets and long-term outcome

Gülşen Akman‐Demir, Erdem Tüzün, Sema İçöz et al. · Cytokine · 2008 · 125 citations

Inflammation, Cytokine, Neurobiology Of Disease +15